Across TCGA pan-cancer cohorts, LINC02551 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LINC02551 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LINC02551 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02551 expression acts as an unfavorable survival marker.
UCEC, CHOL, and SARC are the cancer types where LINC02551 Mutation most reproducibly stratifies survival.